- May 10, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Trelstar Depot, Trelstar, Trelstar LA
Synonyms :
triptorelin, triptorelina, triptoreline, triptorelinum
Class :
Class: Antineoplastics and Sub class: GnRH Agonist
Dosage Forms & Strengths:
lyophilized powder for reconstitution
Reconstitution results in suspension for IM injection
3.75 mg per vial
11.25 mg per vial
22.5 mg per vial
3.75
mg
Intramuscular (IM)
4
weeks
or 11.25 mg shown IM for every 12 weeks, or 22.5 mg given IM for every 24 weeks
Dose Adjustments
Renal Dose Adjustments:
There is no adjustment recommended
Liver Dose Adjustments:
There is no adjustment recommended
Dosage Forms & Strengths:
lyophilized powder for reconstitution
22.5mg/vial; reconstitution results in suspension for IM injection
The kit is for single use and contains a drug vial, prefilled diluent syringe, and 21-gauge needle
The dose recommended for >2years is 22.5 mg given IM every 24 weeks
Dose Adjustments
Renal Dose Adjustments:
There is no adjustment recommended
Liver Dose Adjustments:
There is no adjustment recommended
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be a decreased therapeutic efficacy of mifepristone
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be a decreased therapeutic efficacy of albiglutide
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be a decreased therapeutic efficacy of alogliptin
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
it may enhance the risk of QTc prolongation when combined with amifampridine
when both drugs are combined, there may be a decreased therapeutic efficacy of sulfamethoxazole
Adverse drug reactions:
Frequency defined
1-10%
Cough
Diarrhea
Fatigue
Generalized pain
Headache
Hot flushes
Hypertension
Impotence
Injection site pain
Injection site pruritus
Injection site swelling
Insomnia
Pruritus
Spinal cord compression
UTI
Upper respiratory infection
Vaginal bleeding
Vomiting
>10%
Headache
Hot flushes
Injection site pain
Injection site redness
Nasopharyngitis
Skeletal pain
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pronunciation: trip-to-rel-in
Use: It is an anti-cancer agent used to treat advanced prostate cancer.